Iveson T.J. et al. (2018)

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.

Lancet Oncology, 19(4):562-578

doi: 10.1016/S1470-2045(18)30093-7; PMCID: PMC5883334

Gray V. et al. (2019)

Pattern Recognition Receptor Polymorphisms as Predictors of Oxaliplatin Benefit in Colorectal Cancer.

Journal of the National Cancer Institute, 111(8):828-836

doi: 10.1093/jnci/djy215; PMCID: PMC6695319

Roseweir A.K. et al. (2020)

Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer.

The Journal of Pathology Clinical Research, 6(4):283-296

doi: 10.1002/cjp2.171; PMCID: PMC7578335

Alexander P.G. et al. (2021)

The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer.

British Journal of Cancer, 124(4):786-796

doi: 10.1038/s41416-020-01168-x; PMCID: PMC7884404

Wagner S.J. et al. (2023)

Transformer-based biomarker prediction from colorectal cancer histology: A large-scale multicentric study.

Cancer Cell, 41(9):1650–1661.e4.

doi: 10.1016/j.ccell.2023.08.002; PMID: 37652006

Frei A.L. et al. (2023)

Accounting for intensity variation in image analysis of large-scale multiplexed clinical trial datasets.

The Journal of Pathology: Clinical Research, 9(6):449-463

doi: 10.1002/cjp2.342; PMCID: PMC10556275

Frei A.L. et al. (2024)

Multiplex analysis of intratumoural immune infiltrate and prognosis in patients with stage II-III colorectal cancer from the SCOT and QUASAR 2 trials: a retrospective analysis.

Lancet Oncology, 25(2):198-211

doi: 10.1016/S1470-2045(23)00560-0

Pennel K.A.F. et al. (2024)

JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors.

Journal of Experimental & Clinical Cancer Research, 43(1):64

doi: 10.1186/s13046-024-02958-4; PMCID: PMC10905886

Domingo E. et al. (2024)

Prognostic and Predictive Value of Immunoscore in Stage III Colorectal Cancer: Pooled Analysis of Cases From the SCOT and IDEA-HORG Studies.

Journal of Clinical Oncology, 42(18):2207-2218

doi: 10.1200/JCO.23.01648; PMCID: PMC11185918

Nowak M. et al. (2024)

Single-cell AI-based detection and prognostic and predictive value of DNA mismatch repair deficiency in colorectal cancer.

Cell Reports Medicine, 5(9):101727

doi: 10.1016/j.xcrm.2024.101727; PMCID: PMC11525017